

Edwin P Alyea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3298579/publications.pdf>

Version: 2024-02-01

57
papers

3,216
citations

257101

24
h-index

223531

46
g-index

59
all docs

59
docs citations

59
times ranked

5087
citing authors

#	ARTICLE	IF	CITATIONS
1	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	13.9	488
2	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	0.8	359
3	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	0.8	339
4	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-CD25 Inhibitor to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	0.8	258
5	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3128-3135.	0.8	180
6	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	0.6	156
7	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015, 33, 4167-4175.	0.8	149
8	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016, 127, 646-657.	0.6	145
9	Comparative Outcomes of T-Cell-Depleted and Non-T-Cell-Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion. <i>Journal of Clinical Oncology</i> , 1999, 17, 561-561.	0.8	108
10	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.	0.6	92
11	IL-1 Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018, 131, 1372-1379.	0.6	81
12	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. <i>Blood</i> , 2017, 130, 91-94.	0.6	78
13	CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. <i>Cancer Research</i> , 2002, 62, 5517-5522.	0.4	68
14	Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2018, 379, 1846-1850.	13.9	66
15	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	0.6	62
16	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. <i>Blood</i> , 2015, 126, LBA-8-LBA-8.	0.6	59
17	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	2.5	52
18	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45

#	ARTICLE	IF	CITATIONS
19	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 499-505.	1.7	43
20	Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. <i>Cell Reports</i> , 2021, 37, 109992.	2.9	37
21	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.0	36
22	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 910-918.	2.0	32
23	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.	1.7	31
24	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	0.6	30
25	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2725-2729.	0.6	29
26	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1251-1259.	1.7	27
27	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, 1222-1227.	1.7	24
28	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 4113-4123.	2.5	22
29	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	17
30	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 1881-1893.	2.5	16
31	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	1.7	15
32	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	1.3	15
33	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017, 19, 272-284.	0.3	13
34	The Utility of Routine Chest Radiography in the Initial Evaluation of Adult Patients With Febrile Neutropenia Patients Undergoing HSCT. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 184-189.	2.3	11
35	Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 239-250.	0.7	9
36	Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. <i>Journal of Clinical Apheresis</i> , 1995, 10, 139-143.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. Blood, 2004, 104, 351-351.	0.6	3
38	Patients Who Respond to Donor Lymphocyte Infusion (DLI) Have an Antibody Response Against PDC-E2, the Immunodominant Autoantigens of Primary Biliary Cirrhosis (PBC), but with Different Specificity.. Blood, 2005, 106, 3105-3105.	0.6	3
39	The Evolving Role of Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2015, 10, 18-27.	1.2	2
40	Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 1834-1834.	0.6	2
41	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. Blood, 2004, 104, 2251-2251.	0.6	2
42	Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2016, 128, 387-387.	0.6	2
43	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	0.6	2
44	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis.. Blood, 2006, 108, 2929-2929.	0.6	1
45	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. Blood, 2007, 110, 2016-2016.	0.6	1
46	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. Blood, 2004, 104, 1227-1227.	0.6	0
47	PDC-E2, a Common Auto Antigen in Primary Biliary Cirrhosis (PBC) Is Also a Target of an Antibody Response in Patients Who Achieve Complete Remission after Donor Lymphocyte Infusion.. Blood, 2004, 104, 2121-2121.	0.6	0
48	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	0.6	0
49	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. Blood, 2004, 104, 3317-3317.	0.6	0
50	Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.. Blood, 2005, 106, 1797-1797.	0.6	0
51	Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation.. Blood, 2006, 108, 2977-2977.	0.6	0
52	Effective Graft-Versus-Leukemia Responses Are Associated with the Presence of Nucleic Acid-Immunoglobulin Complexes That Stimulate TLR8 and TLR9.. Blood, 2006, 108, 188-188.	0.6	0
53	Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2006, 108, 757-757.	0.6	0
54	Developing Novel Approaches To Comprehensively Assess T Cell Repertoire Dynamics In The Early Post-Transplant Period. Blood, 2013, 122, 4618-4618.	0.6	0

#	ARTICLE	IF	CITATIONS
55	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3425-3425.	0.6	0
56	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 820-820.	0.6	0
57	Daratumumab for Delayed Red Cell Engraftment after Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 2545-2545.	0.6	0